Aarey Drugs & Pharmaceuticals Ltd Directors Report

To,

The Shareholders,

Your Directors have pleasure in presenting the Thirty Fifth Annual Report together with Audited Accounts for the year-ended 31^stMarch, 2025.

FINANCIAL RESULTS:

Particular	31st March, 2025	31st March, 2024
Income	4,83,75,56,668.93	4,02,58,27,917.41
Expense	4,77,65,37,996.57	3,97,23,98,726.33
(Loss )/ Profit Before Exceptional Item & Tax	6,10,18,672.36	5,34,29,191.08
Profit Before Tax	6,10,18,672.36	5,34,29,191.08
(Less)/ Add: Tax Expenses	2,07,79,932.47	65,92,519.40
Balance Carried To Balance Sheet	4,02,38,739.89	4,68,36,671.68

REVIEW OF OPERATIONS & FUTURE OULLOOK

Our company is manufacturing the following intermediates- Mono Methyl Urea, Die Methyl Urea. Ortho Para Nitro Anisole, 2 Bromomethyl 1,3 Dioxalane &Uracile& in Active Pharma Ingredients the company is involved in manufacturing Metformin HCL, Mefenamic Acid & Doxophylline. Besides we intend to increase capacity of all the products based upon the demand of the product and also plans to do backward & forward integration of products such as DMA-HCL, Ortho chloro benzoic acid and further APIs like the ophylline. Necessary steps has been initiated.

DIVIDEND

Your directors do not recommend any dividend for the year ended 31^stMarch, 2025.

DEPOSITS

The Company has not accepted the deposits from the public as per the Section in accordance with the provisions of Section 73 and 76, and other applicable provisions of Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014.

TRANSFER TO RESERVE:

Your Company has transferred Rs. 40,238,740 to the General Reserves during the year under review.

CHANGES IN SHARE CAPITAL, IF ANY:

Share Capital of the Company is 2,84,54,303 shares.

During the financial year, Company has allotted 4,00,000 shares issued as on 1^st October, 2024 which increased the paid up share capital to 2,84,54,303 shares.

The company has not received the listing approval for 1,00,000 shares hence the Listed Capital is 2,83,54,303 shares.

SUBSIDIARY / HOLDING COMPANY, ETC.:

The Company does not have any Subsidiary, Holding Company, Associate or Group Venture Company. VIGIL MECHANISM

Pursuant to the requirements laid down under Section 177 of the Companies Act, 2013 and Regulation 22 of the SEBI Listing Regulations, the Company has well laid down Vigil Mechanism. The details of the same are provided in the Report on Corporate Governance forming part of this Annual Report. During the year, the Company did not receive any complaint under Vigil mechanism.

CORPORATE SOCIAL RESPONSIBILITY

In accordance with the provisions of Section 135 of the Companies Act, 2013 read with Companies (Corporate Social Responsibility Policy) Rules, 2014, as amended from time to time, the Board of Directors of the Company has constituted Corporate Social Responsibility (CSR) Committee Corporate Social Responsibility (CSR) is a good way of conducting business by which corporate entities visibly contribute to the society. The essence of CSR is to integrate the economic, environment and social objectives of the companys operations and growth. CSR is the process by which the organization thinks about and evolves its relationship with the society and demonstrates its commitment by giving back to the society for the resources it used.

The Composition, particulars of Meeting held and attendances there at are mentioned in the Corporate Governance Report forming part of the Annual Report.

The key philosophy of all CSR initiatives of the Company is guided by three core commitments of Scale, Impact and Sustainability.

During the financial year 2024-25, the Company recorded a Net Profit of Rs. 4,02,38,739.89. As this amount falls below the threshold specified under Section 135(1) of the Companies Act, 2013, the Company is not required to undertake any Corporate Social Responsibility (CSR) activities for the said financial year. Accordingly, no CSR expenditure has been incurred.

DIRECTORS AND KEY MANAGERIAL PERSONNEL

As on 31^stMarch 2025, the Board consists of six members, two of whom are Executive Directors and 3 are Non-Executive Independent Directors and one is Non-Executive Non Independent Director.

Pursuant to the provisions of Section 203 of the Act, Mihir R Ghatalia Managing Director, Mrs. Mira Ghatalia, Chief Financial Officer and Mr. Kailash Chand Jethlia, Company Secretary are the Key Managerial Personnel of the Company as on the date of this Report.

INTER-SE RELATIONSHIP BETWEEN DIRECTORS:

Mihir R Ghatalia Managing Director and Nimit R Ghatalia Director are relatives (siblings). Apart from this none of the Directors of the Company are in any way related to each other.

DIRECTORS RESPONSIBILTY STATEMENT

As referred to in clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013, the Directors hereby confirm:

a) That in preparation of the Annual Accounts for the year ended 31^stMarch, 2025, the applicable accounting standards had been followed along with proper explanation relating to material departures, if any;

b) that the directors had selected such accounting policies and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give true and fairview of the state of affairs of the company at the end of financial year ended 31st March, 2025 and the profit/ (Loss) of the Company for the year under review;

c) that proper and sufficient care has been taken for maintenance of adequate accounting records in accordance with the provisions of the Companies Act ,2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

d) That the annual accounts for the year ended 31^stMarch, 2025 have been prepared on a "going concern basis"

e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.

f) they devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

ANNUAL RETURN

Annual Return as provided under Section 92(3) and Section 134(3)(a) of the Companies Act, 2013, is available on the website of the Company at http://www.aareydrugs.com/pdf/annual-return/MGT-7.pdf

AUDITORS

M/s. Motilal& Associates, Chartered Accountants (Firm Registration No: 106584W) were re-appointed as Statutory Auditors of the Company at the 35^hAnnual General Meeting held on 29^th September, 2025 for a 2^nd term of five consecutive years from the conclusion of this Annual General Meeting to until the conclusion of 40^thAnnual General Meeting of the Company.

SECRETARIAL AUDIT REPORT

The Secretarial Audit Report pursuant to the provisions of Section 204 for the financial year 2024-25 was obtained from M/s. Ashika Shetty, Practicing Company Secretaries, the report which is Self-Explanatory is annexed hereto as Annexure A.

MEETINGS

During the financial year 2024-25, 9 (Nine) meetings of the Board of Directors and 6 (Six) meetings of the Audit Committee were held. Details of these meetings and other Committees of the Board/General Meeting are given in the Report on Corporate Governance forming part of this Annual Report.

DECLARATION OF INDEPENDENCE BY INDEPENDENT DIRECTOR

All the Independent Directors of the Company have furnished a declaration to the effect that they meet the criteria of independence as provided in Section 149(6) of the Act and Regulation 16(1)(b) and Regulation 25 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations). In the opinion of the Board, all the Independent Directors possess the integrity, expertise and experience including the proficiency required to be Independent Directors of the Company, fulfill the conditions of independence as specified in the Act and the Listing Regulations and are independent of the management and have also complied with the Code for Independent Directors as prescribed in Schedule IV of the Companies Act,2013

PERFORMANCE EVALUATION AND ITS CRITERIA:

The Board of Directors carried out an evaluation of its own performance, of the Board, Committees and of the individual Directors pursuant to the provisions of the Act and Corporate Governance requirements as prescribed by the Listing Regulations.

The performance of the Board and its Committees was evaluated by the Board after seeking inputs from the Board / Committee Members based on criteria such as composition of the Board / Committees and structure, effectiveness of the Board / Committee processes, providing of information and functioning etc. The Board and the Nomination and Remuneration Committee reviewed the performance of individual Directors based on criteria such as attendance in Board / Committee meetings, contribution in the meetings like preparedness on issues to be discussed etc.

The Independent Directors at its separate meeting held on 10^th February, 2025 reviewed the performance of Non-Independent Directors and performance of the Board as a whole, performance of

the Chairman of the Company taking into account the views of Executive and Non-executive Directorsand assessed the quality, quantity and timeliness of flow of information to the Board to perform their duties effectively and reasonably

PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS:

The details of Loans given, Guarantees given and Investments made, if any and covered under the provisions of Section 186 of the Act, read with Companies (Meetings of Board and Its Powers) Rules, 2014 are given in the notes to the Financial Statements forming part of this Annual Report.

COMMITTEES OF THE BOARD

The details of the powers, functions, composition and meetings of the Committees of the Board held during the year are given in the Report on Corporate Governance section forming part of this Annual Report.

AUDIT COMMITTEE

The details pertaining to the composition, terms of reference, etc. of the Audit Committee of the Board of Directors of the Company and the meetings thereof held during the financial year are given in the Report on Corporate Governance section forming part of this Annual Report. The recommendations of the Audit Committee were accepted by the Board of Directors of the Company from time to time.

CORPORATE GOVERNANCE

A separate report on Corporate Governance is produced as a part of the Annual Report along with the Auditors statement on its compliance.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION & FOREIGN EXCHANGE EARNINGS AND OUTGO:

Your Company has made the necessary disclosures in this Report in terms of Section 134(3) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014is given in Annexure B and forms part of this report.

INTERNAL FINANCIAL CONTROL SYSTEM

The Board is responsible for establishing and maintaining adequate internal financial control as per Section 134 of the Act.

Your Company has in place an adequate system of internal controls to ensure compliance with various policies, practices and statutes. It has procedures covering all financial and operating functions and processes. These have been designed to provide a reasonable assurance with regards to maintaining of proper accounting controls for ensuring reliability of financial reporting, monitoring of operations, protecting assets from unauthorized use or losses and compliance with regulations. Key controls have been tested during the year and corrective and preventive actions are taken for any weakness.

CHANGE IN THE NATURE OF BUSINESS (IF ANY):

There is no material change in the type of business the Company is carrying.

DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS (IF ANY):

The Directors of your Company confirm that no frauds or instances of mis-management were reported by the Statutory Auditors under sub-section (12) of Section 143 of the Companies Act, 2013.

COMPLIANCE WITH SECRETARIAL STANDARDS:

The Directors state that applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to Meetings of the Board of Directors and General Meetings, respectively, have been duly followed by the Company.

MATERIAL CHANGES AND COMMITMENT:

Except as disclosed elsewhere in the Report, there have been no material changes and commitment affecting, the financial position of your Company, which have occurred between the end of the financial year of the Company and the date of this Report.

SIGNIFICANT AND MATERIAL ORDERS:

No significant and material order has been passed by the Regulators or Courts or Tribunals impacting the going concern status and Companys operations in future.

PARTICULARS OF RELATED PARTY TRANSACTIONS:

All transactions entered into with related parties during the financial year were in the ordinary course of business and on arms length basis and do not attract the provisions of Section 188(1) of the Act. Suitable disclosures as required by the Indian Accounting Standards (IndAS-24) have been made in the notes to the Financial Statements. The Board has a policy for related party transactions which has been uploaded on the Companys website http://www.aareydrugs.com/pdf/2-Related-Party- Transaction.pdf

There were no material Related Party Transactions during the year. Accordingly, Form No. AOC-2, prescribed under the provisions of Section 134 (3)(h) of the Act and Rule 8 of the Companies (Accounts) Rules, 2014, for disclosure of details of Related Party Transactions, which are not "not at arms length basis" and also which are "material and arms length basis", is not provided as an annexure to this Report as it is not applicable.

PREVENTION, PROHIBITION AND REDRESSAL OF SEXUAL HARASSMENT OF WOMEN:

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at the Workplace (Prevention, Prohibition and Redressal) Act, 2013.

Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary and trainees) are covered under this policy who are also provided training about the Act.

During the year under review, no complaint was received.

POLICIES AND DISCLOSURE REQUIREMENTS:

In terms of provisions of the Act and the Listing Regulations, the Company has adopted all the applicable policies. The policies are available on the website of the Company at_ http://www.aareydrugs.com/

All Directors and Senior Management Personnel have affirmed their adherence to the provisions of the Code of Conduct during the financial year 2024-25.

The Companys policy on Directors appointment, remuneration and other matters provided in Section 178(3) of the Act forms part of Nomination and Remuneration Policy and has been disclosed in the Corporate Governance Report.

CORPORATE GOVERNANCE & VIGIL MECHANISM:

A separate Corporate Governance Report on compliance with Corporate Governance requirements as required under Regulation 34(3) read with Schedule V to the Listing Regulations forms part of this Annual Report. The same has been reviewed and certified by Mr. Virendra G. Bhatt, Practicing Company Secretary, the Secretarial Auditors of the Company and Compliance Certificate in respect thereof is attached as Certificate of Corporate Governance

RISK MANAGEMENT:

The Company has its Risk Management Plan & Policy in place which is also displayed on the website of the Company. In the opinion of the Board, during the financial year 2024-25, no elements of risk which may threaten the existence of the Company were noticed by the Board. The Committee monitors the risk management plan and ensures its effectiveness. The details of Committee are set out in the Corporate Governance Report

MANAGEMENT DISCUSSION AND ANALYSIS REPORT:

Managements Discussion and Analysis Report for the year under review, as stipulated under the Listing Regulations, is presented in a separate section, forming part of this Report.

PROMOTERS:

The Promoter Groups holding in the Company as on 31^stMarch, 2025 was 44.80% of the Companys paid up Equity Capital. The members may note that the shareholding and other details of Promoters has been provided in Annual Return.

DISCLOSURE REGARDING MAINTENANCE OF COST RECORDS UNDER SECTION 148 OF THE COMPANIES ACT, 2013:

During the year under review, Maintenance of cost records under section 148 of Companies Act, 2013 is not applicable to the Company as the Company did not carry on any activity as specified in Table A and B of Rule 3 of the Companies (Cost Records and Audit) Rules, 2014.

EMPLOYEES:

There were no employees coming under the purview of Section 197(12) of the Act read with Rules 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014and the rules frame there under

REMUNERATION:

As per Section 197of the Companies Act, 2013, the ratio of remuneration of each director to the median remuneration of the employees of the company for the financial year:

Name of the Director	Ratio to Median employees
Mihir R Ghatalia, Managing Director	5:3

DISCLOSURE UNDER SECTION 164

None of the Directors of the company are disqualified for being appointed as Directors as specified under section 164 of the Companies Act, 2013.

ACKNOWLEDGEMENTS

Your Directors wish to place on record, the appreciation for the continued support of the customers, Bankers and Suppliers. Your Directors acknowledge and thank the employees for their valuable contribution and involvement.

For and on behalf of the Board of Directors

ANNEXURE TO DIRECTORS REPORT Annexure-A

Form No.: MR-3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31^st MARCH, 2025

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,

The Members,

Aarey Drugs and Pharmaceuticals Limited

I have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Aarey Drugs and Pharmaceuticals Limited having CIN- L99999MH1990PLC056538 (hereinafter called "the Company"). Secretarial Audit was conducted in a manner that provides me a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing my opinion thereon.

Based on my verification of the Companys statutory registers, papers, minute books, forms and returns filed with the Registrar of Companies ("ROC"), soft copy of the various records sent over mail as provided by the Company and other relevant records maintained by the Company and also the information provided by the Company, its officers and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on 31^st March, 2025 ("audit period"), has prima facie complied with the statutory provisions listed hereunder:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31^st March, 2025 according to the provisions of:

(i) The Companies Act, 2013 (the Act) and the rules made there under;

(ii) The Securities Contracts (Regulation) Act, 1956 (SCRA) and the rules made there under and the Regulations, Circulars, Guidelines issued thereunder;

(iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;

(iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment and Overseas Direct Investment and External Commercial Borrowings;

(v) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;

(vi) The Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ("the SEBI Act") viz:-

(a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

(b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

(c) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015;

Though the following laws are prescribed in the format of Secretarial Audit Report by the Government, the same were not applicable to the Company for the financial year ended 31^st March, 2025:-

(a) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;

(b) Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021;

(c) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018;

(d) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021;

(e) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;

(vii) The Management has identified and confirmed the other laws as specifically applicable to the Company and that it has proper system to comply with the provisions of the respective Acts, Rules and Regulations;

I have also examined compliance with the applicable clauses of the following and I am of the opinion that the Company has prima facie complied with applicable provisions:

(a) Secretarial Standards 1 and 2 issued by the Institute of Company Secretaries of India.

(b) The Listing Agreements entered into by the Company with the Stock Exchanges read with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

During the period under review, the Company has prima facie complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. as mentioned above subject to the following observations:

(i) The listed entity has not made required disclosures in the notice of EGM w.r.t. issue of shares on preferential basis as per SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 Also, BSE issued observations on the same.

(ii) The warrants, which were allotted on 27 March, 2024 were kept under lock-in from 30 December, 2024, i.e. with a delay of more than 9 months from the date of allotment of warrants.

(iii) The Listed entity has filed Corporate Governance Report for the quarter ended 30 September, 2024 and quarter ended 31 December, 2024 on time, however the revised filings for the said quarters have been filed beyond the prescribed time.

(iv) As on 31 March 2025, paid up share capital of the Company is 2,84,54,303 shares which is agreed with the books of accounts of the Company. The company allotted 4,00,000 shares issued as on 1 October 2024 which increased the paid-up capital to 2,84,54,303 shares, however RTA is showing 1,00,000 shares less in their paid-up share capital. The reason for the same is as cited below:

The Company has not received listing approval for one of the allottee named Watco Chennai Real Estate Pvt Ltd for 1,00,000 shares as the allottee has traded during the approval stage, hence both the stock exchange has withheld the approval of allottee Watco Chennai Real Estate Pvt Ltd, hence there is a difference of the said 1,00,000 shares. The Company has received approval for rest of the allottees except Watco Chennai Real Estate Pvt. Ltd. Both the stock exchanges have not decided the matter yet.

(iv) The listed entity has maintained software for the structured digital database; however, no data could be found from the said software as on 31 March 2025. However subsequently data was recovered. Basis the information provided, I am of opinion that the listed entity

has prima facie complied Regulation 3(5) & 3(6) SEBI (Prohibition of Insider Trading) Regulations, 2015.

(v) The Company has not produced sufficient evidence to show that it has submitted Annual Report with the District Officer as required under The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

I further report that:-

1. I have not examined the Financial Statements, Financial books, related financial Acts and Related Party Transactions etc., For these matters, I rely on the report of statutory auditors for Financial Statement for the financial year ended 31^st March, 2025.

2. The Board of Directors of the Company is constituted with proper balance of Executive Directors, Non-Executive Directors, Independent Directors and Woman Director. The changes in the composition of the Board of Directors that took place during the audit period under review were prima facie carried out in compliance with the provisions of the Act.

3. As per the information provided, the Company has prima facie given adequate notice to all the directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance.

4. I was informed and I observed from the minutes of the Board and Committee Meetings that all the decisions at the Meetings were prima facie carried out unanimously.

5. There are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

6. The management is responsible for compliances of all business laws. This responsibility includes maintenance of statutory registers/files required by the concerned authorities and internal control of the concerned department.

7. During the audit period, the Company had filed Forms required to be filed within prescribed time and few forms with additional fees.

8. I further report that during the audit period, following events have taken place:

a. Obtained approval from its members at the 34^th Annual General Meeting of the Company held on 30 September 2024 for giving loan(s), guarantee(s) or providing security(ies) under section 185 of the Companies Act, 2013 up to an aggregate limit of Rs. 200 Crores.

b. Obtained approval from its members at the Extra-Ordinary General Meeting of the Company held on 2January 2025 for Issuance of 50,00,000 warrants convertible into equity shares of the Company on preferential basis.

9. During the audit period, the Company has allotted 400000 Convertible Warrants at a price of Rs. 37.80 per warrant for which the Company received 25% consideration at the time of allotment of the Convertible Warrants (balance consideration to be received as and when the warrant holders exercise their conversion rights).

10. I further report that during the audit period, there were no instances of:

i. Public/ Rights/debentures/ sweat equity, etc.;

ii. Issue of equity shares under Employee Stock Option Scheme;

iii. Redemption / Buy- Back of securities;

iv. Merger / amalgamation / reconstruction etc.;

v. Foreign Technical Collaborations.

I further report that:

1. Maintenance of Secretarial record is the responsibility of the Management of the Company. My responsibility is to express an opinion on these Secretarial Records based on my audit.

2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in the Secretarial records. I believe that the processes and practices, I followed provide a reasonable basis for my opinion.

3. Where ever required, I have obtained the Management representation about the compliance of Laws, Rules and Regulations and happening of events etc.

4. I have not verified the correctness and appropriateness of financial records and Books of Accounts of Company.

5. The compliance of the provisions of Corporate and other applicable Laws, Rules, Regulations, Standards is the responsibility of the Management. My examination was limited to the verification of procedures on test basis.

6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor the efficacy or effectiveness with which the Management has conducted the affairs of the Company.

7. Due to the inherent limitations of an audit including internal, financial and operating controls, there is an unavoidable risk that some Misstatements or material non-compliances may not be detected, even though the audit is properly planned and performed in accordance with the Standard.

ANNEXURE-B

PARTICULARS OF CONSERVATION OF ENERGY, TECHNOLOGY ABSORBTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO AS REQUIRED UNDER SECTION 134 (3) (m) OF THE COMPANIES ACT, 2013, READ WITH THE COMPANIES (DISCLOSURE OF PARTICULARS IN THE REPORT OF BOARD OF DIRECTORS) RULES,1988.

1) CONSERVATION OF ENERGY

a) Energy conservation measures taken:

1) The Company has been strictly observing and monitoring the power consumption.

ii) The grinding operation with keeping the automatic regular of feeds has been maintained to minimize power consumption.

iii) Dual Fuel Burner was installed.

b) Impact of above measures:

High power factor above 0.9 and optimization of the grind ability has been maintained.

2) POWER AND FUEL CONSUMPTION

Particulars	2024-2025	2023-2024
(i) Electricity Purchased
Units (KWH)	9,47,152 KWH	8,98,018 KWH
Total Amount (^)	1,12,39,700	1,01,07,210
Rate/Unit (^)	11.86	11.143
(ii) Own generation
a) Through diesel generator	3,563 KWH	3,468 KWH
Units per litre of Diesel Oil	3.3 KWH	3.3 KWH
Cost/Unit (^)	27.90	27.90
b) Through steam turbine/generator	NIL	·
Units per litre of fuel oil/gas	NIL	·
Cost/Unit (^)	NIL	·
Particulars	2024-2025	2023-2024
(iii) Coal
Quantity (Tons)	281.441	NIL
Total Cost (^)	26,45,545	NIL
Average Rate (^/MT)	9.40	·
(iv) Furnace Oil / Diesel (Diesel/LDO)
Quantity (M.T.)	1.44 / 24.04	1.4 / 14.33
Total Amount (^)	1,09,308 / 12,48,422	1,28,940 / 9,31,645
Average Rate (^)	91.09 / 61.80	92.10 / 65
(v) Others / Internal Generation (Biomass Briquette)
Quantity (MT)	1092.77	994.45
Total Cost (^)	99,44,207	91,48,986
Rate/Unit (^)	9,100 / MT	9,200 / MT

3) ACTUAL PRODUCTION

Particulars	2024-2025 (MTS)	2023-2024 (MTS)
Total Production	2,590.23 MT	490.58 MT

RESEARCH & DEVELOPMENT (R&D)

Quantity (in MTS)

Particulars	2024-2025	2023-2024
Total Production	2,590.23 MT	490.58 MT

Research & Development (R&D)

Particulars	Details
Specific areas in which R&D is conducted by the Company	-
Benefits derived as a result of the above R&D	-
Further Plan of Action	-
Management Review	-

Expenditure on R&D

Particulars	2024-2025 (INR)	2023-2024 (INR)
a) Capital	1,24,00,000	507,405
b) Recurring
Total	[Insert total]	[Insert total]
c) R&D Expenditure as % of Turnover	[To be given]	[To be given]

4) TECHNOLOGY ABSORPTION, ADAPTATION AND INNOVATION

Particulars	2024-2025 (^)	2023-2024 (^)
a) Efforts, in brief, made towards technology absorption, adaptation and innovation	·	·
b) Benefits derived as a result of the above	·	·
c) Imported Technology (last 5 years)
1. Technology import	·	·
2. Year of import	·	·
Particulars	2024-2025 (K)	2023-2024 (K)
3. Has technology been fully absorbed	·	·
4. If not fully absorbed, areas where this has not taken place, reasons therefor and future plans of action	·	·

5) FOREIGN EXCHANGE EARNINGS AND OUTGO

Particulars	2024-2025(K)	2023-2024(K)
Activities relating to exports; initiatives taken to increase exports; development of new export markets for products & services; and export plans	·	·
Total Foreign Exchange Used	1108.20 Lakh	566.09 Lakh
Total Foreign Exchange Earned (FOB)	298.23 Lakh	140.61 Lakh